LAMEA Atrial Fibrillation Market Size, Share & Industry Trends Analysis Report by End-user, Type, Technology, Country and Growth Forecast, 2022-2028

The Latin America, Middle East and Africa Atrial Fibrillation Market would witness market growth of 11.7% CAGR during the forecast period (2022-2028).

Direct cardiac auscultation is advised for establishing the heart rate in atrial fibrillation. The most serious indication that needs quick attention is low blood pressure. Due to the decreased cardiac output, many of the symptoms of untreated atrial fibrillation are signs of congestive heart failure. When respiratory distress is present, the affected person's breathing rate frequently rises.

Using pulse oximetry, any precipitating causes, such as pneumonia, may be linked to insufficient oxygen reaching the body's tissues. A jugular vein examination may demonstrate increased pressure (jugular venous distention). When the lungs are examined, crackles may be heard which might be signs of pulmonary edema. A quick, uneven beat will be visible during a cardiac examination.

Although it can happen in otherwise healthy hearts, atrial fibrillation is associated with several cardiovascular diseases. High blood pressure, coronary artery disease, mitral valve stenosis (caused, for example, by rheumatic heart disease or mitral valve prolapse), left atrial enlargement, congenital heart disease, mitral regurgitation, hypertrophic cardiomyopathy (HCM), pericarditis, and prior heart surgery are among the cardiovascular conditions known to be linked to the development of atrial fibrillation.

Reviewing epidemiological research on tobacco use prevalence, related health impacts, and strategies for smoking cessation and prevention in the United Arab Emirates was the goal. By increasing the expense of smoking through taxing, launching persistent social marketing programs, and guaranteeing that health experts regularly counsel smokers to stop smoking together with behavioural and pharmaceutical assistance for cessation, the UAE Government has shown great efforts.

The Brazil market dominated the LAMEA Atrial Fibrillation Market by Country in 2021; thereby, achieving a market value of $62.5 million by 2028. The Argentina market is experiencing a CAGR of 12.3% during (2022-2028). Additionally, The UAE market would witness a CAGR of 11.4% during (2022-2028).

Based on End User, the market is segmented into Hospitals, Specialty Clinics, and Others. Based on Type, the market is segmented into Surgical and Non-Surgical. Based on Technology, the market is segmented into Radiofrequency, Laser, Cryotherapy, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, MicroPort Scientific Corporation, Boston Scientific Corporation, Abbott Laboratories, Medtronic PLC, BIOTRONIK SE & Co. KG, Koninklijke Philips N.V., Siemens Healthineers AG (Siemens AG) and AtriCure, Inc.

Scope of the Study

Market Segments Covered in the Report:

By End User

• Hospitals
• Specialty Clinics
• Others

By Type

• Surgical
• Non-Surgical

By Technology

• Radiofrequency
• Laser
• Cryotherapy
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Johnson & Johnson
• MicroPort Scientific Corporation
• Boston Scientific Corporation
• Abbott Laboratories
• Medtronic PLC
• BIOTRONIK SE & Co. KG
• Koninklijke Philips N.V.
• Siemens Healthineers AG (Siemens AG)
• AtriCure, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free